This review clearly presents the interest of taking in charge TBI-associated Alzheimer's dementia and the potential of cinnamon as a neuroprotective agent to counteract TBI-associated dementia in patients. Treatment prices shall be considered as an important issue especially in their use in developing world countries as suggested by the authors. Development of low-cost treatments as cinnamon or others must be privileged to allow treatment of all patients. As a translational perspective, the authors could have discussed how the cinnamon treatment should be envisaged: either by a cinnamon high rich diet (preventive strategy) all lifelong or as a classical "pharmacological" chronic treatment.
